Pavion Blue Capital LLC Purchases Shares of 2,345 Gilead Sciences, Inc. (NASDAQ:GILD)

Pavion Blue Capital LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,345 shares of the biopharmaceutical company’s stock, valued at approximately $217,000.

Several other large investors have also recently bought and sold shares of GILD. HHM Wealth Advisors LLC raised its holdings in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the period. Valued Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences during the fourth quarter worth approximately $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. Finally, Crews Bank & Trust bought a new position in shares of Gilead Sciences during the fourth quarter worth approximately $31,000. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 713,000 shares of company stock valued at $67,945,181 over the last quarter. Insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $109.95 on Friday. The firm has a market cap of $137.03 billion, a PE ratio of 297.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. The firm’s fifty day moving average is $95.41 and its 200-day moving average is $88.73. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $111.03.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is currently 832.43%.

Analyst Ratings Changes

GILD has been the topic of several recent research reports. Morgan Stanley raised their target price on shares of Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. UBS Group raised their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Finally, Barclays increased their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.